CLINICAL_TRIALS
trial_result
· 2025-09-10
Clinical Trial Update: Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma [Phase 2]
Summary
Phase 2 trial evaluating regorafenib in patients with progressive, recurrent, or metastatic adenoid cystic carcinoma has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Adenoid Cystic Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-09-10